vTv Therapeutics appoints four new members to scientific advisory board

HIGH POINT, N.C. - vTv Therapeutics Inc. (NASDAQ:VTVT), a $158 million market cap biotech company that has seen its stock surge over 60% year-to-date according to InvestingPro data, announced Thursday the appointment of four new members to its Scientific Advisory Board (SAB) to guide the clinical development of cadisegliatin, its investigational oral therapy for type 1 diabetes currently in Phase 3 trials.

The new appointees include Alfonso Galderisi, MD, PhD, a pediatric endocrinologist at Yale University; Mark Evans, MD, Professor of Diabetic Medicine at the University of Cambridge; Chantal Mathieu, MD, PhD, Professor of Medicine at the University of Leuven; and Klara Klein, MD, PhD, Assistant Professor at the University of North Carolina at Chapel Hill.

These experts join existing SAB members John Buse, MD, PhD, and Alexander Fleming, MD, to provide strategic guidance on clinical trial planning, study design, and regulatory strategy for cadisegliatin. While the company maintains a strong liquidity position with a current ratio of 4.98 and more cash than debt on its balance sheet, InvestingPro analysis indicates the company is not yet profitable, highlighting the importance of its clinical development programs.

"Their collective experience in diabetes care, clinical research, and regulatory engagement will be invaluable as we advance cadisegliatin and work to bring meaningful innovation to people living with type 1 diabetes," said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics, according to the company’s press release.

Cadisegliatin (TTP399) is being developed as a potential first-in-class oral adjunctive treatment to insulin for type 1 diabetes. The compound is a liver-selective glucokinase activator that, in non-clinical studies, has shown to increase glucokinase activity independently from insulin.

The late-stage biopharmaceutical company is focused on developing oral, small molecule drug candidates for diabetes and other chronic diseases. The safety and efficacy of cadisegliatin have not yet been established through the ongoing clinical trials. With analyst price targets ranging from $35 to $36 and the next earnings report due on November 12, 2025, investors seeking deeper insights into vTv’s financial health and growth prospects can access additional analysis through InvestingPro, which features 13 more exclusive investment tips for this stock.

In other recent news, vTv Therapeutics Inc. announced the commencement of a Phase 3 trial for its oral therapy, cadisegliatin, aimed at treating type 1 diabetes. The trial, named CATT1, has begun with the first participant already randomized. Cadisegliatin is noted as a potential first-in-class treatment, functioning as a liver-selective glucokinase activator. It has received Breakthrough Therapy designation from the U.S. Food and Drug Administration. This designation indicates that the treatment may offer substantial improvement over existing therapies. The compound has shown good tolerance in over 500 subjects during trials lasting up to six months. These developments mark a significant step forward in the company’s research efforts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.